Microsoft India and SRL Diagnostics announced their partnership to expand the AI Network for Healthcare to pathology. This collaboration will help improve the quality of digital pathology for population screening by bringing together Microsoft’s Azure and AI innovations along with SRL’s expertise in the study of cells and tissues (histology). With this addition, Microsoft’s AI Network for Healthcare has now expanded to include pathology along with eye care and cardiology.
SRL Diagnostics said it has a repository of more than a million histopathology slides which would be used for training an AI algorithm. By increasing efficiency in the initial steps in a biopsy tissue analysis through artificial neural networks, it will be possible for a histopathology laboratory to cut down on inadvertent manual errors and process more samples in a day with a higher level of accuracy.
Anil Bhansali, Managing Director, Microsoft India (R&D) Private Limited, said, “Microsoft is committed to empowering both the healthcare industry and patients by using AI to democratize healthcare for all. Our partnership with SRL Diagnostics will assist pathologists by equipping them with technology that will augment their capability. This is the third area where we have expanded our AI Network for Healthcare after eyecare and cardiology. We will continue to look for other areas where we can deploy technology to make healthcare more accessible.”
Growing prevalence of chronic diseases such as cancer is one of the key factors for the need for pathology to transform. Digital pathology is increasingly being preferred as it has helped bring improvement in service delivery, patient safety and communications while reducing errors and lowering costs. A histopathology is a specialized form of pathology for analyzing tissue biopsies (mounted on glass slides) and is used for detecting numerous diseases. Histopathologists require highly efficient tools to assist in diagnosis, thus augmenting the demand for automated and innovative implementation of cloud and AI, said Microsoft India.
Arindam Haldar, Chief Executive Officer, SRL Diagnostics said, “In line with SRL’s vision to help people on their path to better health, we are delighted to be partnering with Microsoft to co-create solutions and generate both social and business value. Diagnosis is the first step to disease management, as without accurate identification of the cause there is no possibility of a precise treatment. With the growing number of samples of cancer, as well as of other diseases, there’s a need to quickly and accurately analyze the samples to help doctors arrive at a diagnosis faster. The AI platform that Microsoft will build in collaboration with SRL is expected to create a software environment infused with millions of data points and knowledge gained from SRL’s expert laboratory professionals.”